Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019

被引：50

作者：

Kissling, Esther ^{[1
,32
]}

Rose, Angela ^{[1
,32
]}

Emborg, Hanne-Dorthe ^{[2
]}

Gherasim, Alin ^{[3
,4
,49
,53
,56
]}

Pebody, Richard ^{[5
,55
,76
]}

Pozo, Francisco ^{[6
,50
,54
,70
,72
]}

Trebbien, Ramona ^{[7
]}

Mazagatos, Clara ^{[3
,4
,49
,53
,56
,69
,71
]}

Whitaker, Heather ^{[5
,55
,76
]}

Valenciano, Marta ^{[1
,32
]}

Filipovic, Sanja Kurecic ^{[8
]}

Visekruna-Vucina, Vesna ^{[8
]}

Novosel, Iva Pem ^{[8
]}

Lovric, Zvjezdana ^{[8
]}

Petrovic, Goranka ^{[8
]}

Drazenovic, Vladimir ^{[9
]}

Vince, Adriana ^{[10
]}

Topic, Antea ^{[10
]}

Mihalic, Jelena Budimir ^{[10
]}

Huljev, Eva ^{[10
]}

Luksic, Boris ^{[11
]}

Karabuva, Svjetlana ^{[11
]}

Cikes, Mihaela ^{[11
]}

Emborg, Hanne-Dorthe ^{[2
]}

Trebbien, Ramona ^{[7
]}

Helmuth, Ida Glode ^{[2
]}

Krause, Tyra Grove ^{[2
]}

Lina, Bruno ^{[12
,13
]}

Falchi, Alessandra ^{[14
]}

Vilcu, Ana-Maria ^{[15
]}

Souty, Cecile ^{[15
]}

Blanchon, Thierry ^{[15
]}

Launay, Titouan ^{[15
]}

van der Werf, Sylvie ^{[16
,17
]}

Enouf, Vincent ^{[16
,17
]}

Behillil, Sylvie ^{[16
,17
]}

Valette, Martine ^{[18
]}

Launay, Odile ^{[19
]}

Lachatre, Marie ^{[20
]}

Lenzi, Nezha ^{[21
]}

L'Honneur, Anne-Sophie ^{[22
]}

Galtier, Florence ^{[23
,24
]}

Olivier, Gaget Olivier ^{[24
,25
]}

Foulongne, Vincent ^{[26
]}

Merle, Corinne ^{[26
]}

Vanhems, Philippe ^{[27
,28
]}

Laine, Fabrice ^{[27
,29
]}

Lagathu, Gisele ^{[30
]}

Carrat, Fabrice ^{[31
]}

Valenciano, Marta ^{[1
,32
]}

机构：

[1] EpiConcept, Paris, France

[2] Statens Serum Inst, Dept Infect Dis Epidemiol & Prevent, Copenhagen, Denmark

[3] Inst Hlth Carlos III, Natl Epidemiol Ctr, Madrid, Spain

[4] Inst Hlth Carlos III, CIBERESP, Madrid, Spain

[5] Publ Hlth England, London, England

[6] Inst Hlth Carlos III, WHO Natl Influenza Ctr, Natl Influenza Reference Lab, Natl Ctr Microbiol, Madrid, Spain

[7] Statens Serum Inst, Dept Virus & Microbiol Special Diagnost, Natl Influenza Ctr, Copenhagen, Denmark

[8] Croatian Inst Publ Hlth, Zagreb, Croatia

[9] Croatian Inst Publ Hlth, Dept Virol, Zagreb, Croatia

[10] Univ Hosp Infect Dis, Zagreb, Croatia

[11] Clin Hosp Ctr Split, Split, Croatia

[12] Grp Hosp Nord HCL, Inst Agents Infectieux, CNR Virus Infect Resp, Lab Virol, Lyon, France

[13] Univ Lyon, UCBL, Fac Med LYON Est, CIRI,Inserm,U1111,Lab Virpath,CNRS 5308,ENS, Lyon, France

[14] Univ Corse, INSERM, Lab Virol, Corte, France

[15] Sorbonne Univ, INSERM, IPLESP, UMRS 1136, F-75012 Paris, France

[16] Univ Paris Diderot SPC, Inst Pasteur, Unite Genet Mol Virus ARN, UMR 3569,CNRS, Paris, France

[17] CNR, Inst Pasteur, Virus Infect Resp, Paris, France

[18] Grp Hosp Nord HCL, Inst Agents Infect, CNR Virus Infect Resp, Lab Virol, Lyon, France

[19] CIC Vaccinol, I REIVAC, Innovat Clin Res Network Vaccinol, Paris, France

[20] CIC Vaccinol, I REIVAC, Paris, France

[21] I REIVAC, Paris, France

[22] Hop Cochin, Serv Virol, Paris, France

[23] CHU Montpellier, INSERM, CIC 1411, I REIVAC, Montpellier, France

[24] CHU Montpellier, Hop St Eloi, Montpellier, France

[25] CHU Montpellier, CIC 1411, INSERM, Montpellier, France

[26] CHU Montpellier, Montpellier, France

[27] I REIVAC, Paris, France

[28] Hop Edouard Herriot, Lyon, France

[29] Hop Pontchaillou, CIC 1414, Rennes, France

[30] CHU Rennes, Lab Virol, Rennes, France

[31] UPMC Univ Paris 06, Dept Publ Hlth, Hop St Antoine, IPLESP,UMRS 1136, Paris, France

[32] EpiConcept, Paris, France

[33] ECDC, Stockholm, Sweden

[34] Robert Koch Inst, Resp Infect Unit, Dept Infect Dis Epidemiol, Berlin, Germany

[35] Robert Koch Inst, Natl Reference Ctr Influenza, Berlin, Germany

[36] HSE Hlth Protect Surveillance Ctr, Dublin, Ireland

[37] European Ctr Dis Prevent & Control ECDC, EPIET, Stockholm, Sweden

[38] Irish Coll Gen Practitioners, Dublin, Ireland

[39] Univ Coll Dublin, Natl Virus Reference Lab, Dublin, Ireland

[40] CIBERESP, Inst Salud Publ Navarra, IdiSNA, Pamplona, Spain

[41] Complejo Hosp Navarra, IdiSNA, Pamplona, Spain

[42] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands

[43] Nivel Netherlands Inst Hlth Serv Res, Utrecht, Netherlands

[44] Inst Nacl Saude Dr Ricardo Jorge, Dept Epidemiol, Lisbon, Portugal

[45] Inst Nacl Saude Dr Ricardo Jorge, Dept Doencas Infeciosas, Lisbon, Portugal

[46] Cantacuzino Natl Med Mil Inst Res & Dev, Bucharest, Romania

[47] Clin Hosp Infect Dis Sf Parascheva, Iasi, Romania

[48] Clin Hosp Infect Dis Dr Victor Babes, Bucharest, Romania

[49] Inst Hlth Carlos III, CIBERESP, Natl Ctr Epidemiol, Madrid, Spain

[50] Inst Hlth Carlos III, WHO Natl Influenza Ctr, Natl Influenza Reference Lab, Natl Ctr Microbiol, Madrid, Spain

来源：

EUROSURVEILLANCE | 2019年 / 24卷 / 08期

关键词：

D O I：

10.2807/1560-7917.ES.2019.24.1900121

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Influenza A(H1N1)pdm09 and A(H3N2) viruses both circulated in Europe in October 2018-January 2019. Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32-43% against influenza A; higher against A(H1N1)pdm09 and lower against A(H3N2). Among hospitalised older adults, VE estimates were 34-38% against influenza A and slightly lower against A(H1N1)pdm09. Influenza vaccination is of continued benefit during the ongoing 2018/19 influenza season.

引用

页码：2 / 14

页数：13

共 19 条

[1]

Covenay J, 2015, FIRTHLOGIT STATA MOD

[2]

Department of Health/ National Health Service (DoH/NHS), 2013, FLU IMM PROGR 2013 1

[3] Interim Estimates of 2018-19 Seasonal Influenza Vaccine Effectiveness - United States, February 2019 [J].

Doyle, Joshua D. ;

Chung, Jessie R. ;

Kim, Sara S. ;

Gaglani, Manjusha ;

Raiyani, Chandni ;

Zimmerman, Richard K. ;

Nowalk, Mary Patricia ;

Jackson, Michael L. ;

Jackson, Lisa A. ;

Monto, Arnold S. ;

Martin, Emily T. ;

Belongia, Edward A. ;

McLean, Huong Q. ;

Foust, Angie ;

Sessions, Wendy ;

Berman, LaShondra ;

Garten, Rebecca J. ;

Barnes, John R. ;

Wentworth, David E. ;

Fry, Alicia M. ;

Patel, Manish M. ;

Flannery, Brendan .

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2019, 68 (06) :135-139

[4]

ECDC, SEAS INFL VACC ANT U

[5]

*ECDC, 2016, SEAS INFL VACC ANT U

[6] Influenza vaccine effectiveness in adults 65 years and older, Denmark, 2015/16-a rapid epidemiological and virological assessment [J].

Emborg, H. ;

Krause, T. G. ;

Nielsen, L. ;

Thomsen, M. K. ;

Christiansen, C. B. ;

Skov, M. N. ;

Nielsen, X. C. ;

Weinreich, L. S. ;

Fischer, T. K. ;

Ronn, J. ;

Trebbien, R. .

EUROSURVEILLANCE, 2016, 21 (14) :2-7

[7]

European Centre for Disease Prevention and Control (ECDC) World Health Organization Regional Office for Europe. (WHO/Europe), 2019, FLU NEWS EUR SUMM WE, V3

[8]

European Centre for Disease Prevention and Control (ECDC) World Health Organization Regional Office for Europe. (WHO/Europe), 2019, FLU NEWS EUR VIR CHA, V6

[9]

European Union (EU), EPICONCEPT I MOVE PR

[10]

European Union (EU), 2015, GEN PROT TEST NEG DE

← 1 2 →